• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies.接受生物和合成靶向治疗的风湿性疾病患者中COVID-19的临床特征和结局
Ann Rheum Dis. 2020 Jul;79(7):988-990. doi: 10.1136/annrheumdis-2020-217948. Epub 2020 Jun 5.
2
Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry.风湿性疾病患者因 COVID-19 住院的相关特征：来自 COVID-19 全球风湿病联盟医生报告登记处的数据。
Ann Rheum Dis. 2020 Jul;79(7):859-866. doi: 10.1136/annrheumdis-2020-217871. Epub 2020 May 29.
3
Clinical course, severity and mortality in a cohort of patients with COVID-19 with rheumatic diseases.一组患有风湿性疾病的COVID-19患者的临床病程、严重程度和死亡率。
Ann Rheum Dis. 2020 Dec;79(12):1659-1661. doi: 10.1136/annrheumdis-2020-218054. Epub 2020 Jun 30.
4
Coronavirus disease 2019 (COVID-19) in autoimmune and inflammatory conditions: clinical characteristics of poor outcomes.2019 年冠状病毒病（COVID-19）在自身免疫和炎症性疾病中的表现：不良结局的临床特征。
Rheumatol Int. 2020 Oct;40(10):1593-1598. doi: 10.1007/s00296-020-04676-4. Epub 2020 Aug 13.
5
National registry for patients with inflammatory rheumatic diseases (IRD) infected with SARS-CoV-2 in Germany (ReCoVery): a valuable mean to gain rapid and reliable knowledge of the clinical course of SARS-CoV-2 infections in patients with IRD.德国炎症性风湿病（IRD）患者感染 SARS-CoV-2 的国家登记处（ReCoVery）：了解 IRD 患者 SARS-CoV-2 感染临床病程的快速可靠知识的宝贵手段。
RMD Open. 2020 Sep;6(2). doi: 10.1136/rmdopen-2020-001332.
6
Susceptibility and severity of COVID-19 in patients treated with bDMARDS and tsDMARDs: a population-based study.接受生物改善病情抗风湿药（bDMARDs）和靶向合成改善病情抗风湿药（tsDMARDs）治疗的患者中COVID-19的易感性和严重程度：一项基于人群的研究。
Ann Rheum Dis. 2020 Jul;79(7):986-988. doi: 10.1136/annrheumdis-2020-217903. Epub 2020 May 28.
7
Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study.COVID-19 住院患者合并慢性炎症和自身免疫性风湿性疾病的临床结局：一项多中心匹配队列研究。
Ann Rheum Dis. 2020 Dec;79(12):1544-1549. doi: 10.1136/annrheumdis-2020-218296. Epub 2020 Aug 12.
8
Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases.COVID-19 相关住院风险因素在自身免疫性炎症性风湿病患者中的分析。
Ann Rheum Dis. 2020 Nov;79(11):1393-1399. doi: 10.1136/annrheumdis-2020-217984. Epub 2020 Aug 7.
9
Biologics, spondylitis and COVID-19.生物制剂、脊柱炎与新型冠状病毒肺炎
Ann Rheum Dis. 2020 Dec;79(12):1663-1665. doi: 10.1136/annrheumdis-2020-217941. Epub 2020 Jun 10.
10
What is the true incidence of COVID-19 in patients with rheumatic diseases?风湿性疾病患者中新型冠状病毒肺炎的真实发病率是多少？
Ann Rheum Dis. 2021 Feb;80(2):e18. doi: 10.1136/annrheumdis-2020-217615. Epub 2020 Apr 22.

引用本文的文献

1
COVID-19 infection characteristics, risk factors and its potential impacts on Takayasu arteritis: a web-based survey in a large cohort.COVID-19 感染特征、危险因素及其对大动脉炎的潜在影响：一项基于网络的大型队列研究。
Front Immunol. 2024 Jan 8;14:1284168. doi: 10.3389/fimmu.2023.1284168. eCollection 2023.
2
Effects of Biologic Therapies on the Chance of COVID-19 Infection Among Rheumatoid Arthritis and Lupus Patients During the First Wave of the Pandemic.大流行第一波期间生物疗法对类风湿性关节炎和狼疮患者感染新冠病毒几率的影响。
Arch Bone Jt Surg. 2022 Nov;10(11):964-968. doi: 10.22038/ABJS.2022.60064.2959.
3
Locomotive syndrome in rheumatoid arthritis patients during the COVID-19 pandemic.类风湿关节炎患者在 COVID-19 大流行期间的运动障碍综合征。
Nagoya J Med Sci. 2022 Nov;84(4):799-812. doi: 10.18999/nagjms.84.4.799.
4
COVID-19 was not associated or trigger disease activity in spondylarthritis patients: ReumaCoV-Brasil cross-sectional data.COVID-19 与脊柱关节炎患者的疾病活动无关或无触发作用：ReumaCoV-Brasil 横断面数据。
Adv Rheumatol. 2022 Nov 22;62(1):45. doi: 10.1186/s42358-022-00268-x.
5
The effect of COVID-19 pandemic in a large series of patients with Takayasu arteritis.COVID-19 大流行对大量 Takayasu 动脉炎患者的影响。
Turk J Med Sci. 2022 Jun;52(3):565-570. doi: 10.55730/1300-0144.5347. Epub 2022 Jun 16.
6
Safety of Biologic-DMARDs in Rheumatic Musculoskeletal Disorders: A Population-Based Study over the First Two Waves of COVID-19 Outbreak.风湿性肌肉骨骼疾病中生物类 DMARDs 的安全性：COVID-19 爆发的前两个波次中的基于人群研究。
Viruses. 2022 Jul 1;14(7):1462. doi: 10.3390/v14071462.
7
Experiences during the COVID-19 Pandemic among People with Inflammatory Arthritis: "Reopening of Society Is Harder than Lock-Down"-A Qualitative Interview Study.炎症性关节炎患者在新冠疫情期间的经历：“社会重启比封锁更艰难”——一项定性访谈研究
Vaccines (Basel). 2022 Jun 21;10(7):982. doi: 10.3390/vaccines10070982.
8
Safety and immunogenicity of inactivated COVID-19 vaccination in adult rheumatic patients in South China: a prospective study.中国南方成年风湿患者中 COVID-19 灭活疫苗接种的安全性和免疫原性：一项前瞻性研究。
Hum Vaccin Immunother. 2022 Nov 30;18(5):2090176. doi: 10.1080/21645515.2022.2090176. Epub 2022 Jul 25.
9
Mortality related to COVID-19 in patients with rheumatic and musculoskeletal diseases, first wave of the outbreak: a single-center study.风湿和肌肉骨骼疾病患者中与COVID-19相关的死亡率，疫情第一波：一项单中心研究
Ther Adv Musculoskelet Dis. 2022 Apr 29;14:1759720X221090296. doi: 10.1177/1759720X221090296. eCollection 2022.
10
COVID GEAS: COVID-19 National Survey in Patients With Systemic Autoimmune Diseases.COVID GEAS：系统性自身免疫性疾病患者的COVID-19全国调查。
Front Med (Lausanne). 2022 Jan 27;8:808608. doi: 10.3389/fmed.2021.808608. eCollection 2021.

本文引用的文献

1
Covid-19 in Immune-Mediated Inflammatory Diseases - Case Series from New York.免疫介导性炎症疾病中的新冠病毒病——来自纽约的病例系列
N Engl J Med. 2020 Jul 2;383(1):85-88. doi: 10.1056/NEJMc2009567. Epub 2020 Apr 29.
2
Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries.风湿性疾病与2019冠状病毒病：来自2019冠状病毒病全球风湿病联盟医疗服务提供者登记处的初步数据。
Lancet Rheumatol. 2020 May;2(5):e250-e253. doi: 10.1016/S2665-9913(20)30095-3. Epub 2020 Apr 16.
3
COVID-19 and immunomodulation in IBD.COVID-19 与 IBD 中的免疫调节。
Gut. 2020 Jul;69(7):1335-1342. doi: 10.1136/gutjnl-2020-321269. Epub 2020 Apr 17.
4
Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies.一系列接受免疫抑制靶向治疗的慢性关节炎患者的 COVID-19 临床病程。
Ann Rheum Dis. 2020 May;79(5):667-668. doi: 10.1136/annrheumdis-2020-217424. Epub 2020 Apr 2.
5
COVID-19 infection and rheumatoid arthritis: Faraway, so close!COVID-19 感染与类风湿关节炎：远在天边，近在咫尺！
Autoimmun Rev. 2020 May;19(5):102523. doi: 10.1016/j.autrev.2020.102523. Epub 2020 Mar 20.

Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies.

作者信息

Sanchez-Piedra Carlos, Diaz-Torne Cesar, Manero Javier, Pego-Reigosa José M, Rúa-Figueroa Íñigo, Gonzalez-Gay Miguel A, Gomez-Reino Juan, Alvaro-Gracia Jose M

机构信息

Research Unit, Sociedad Española de Reumatologia, Madrid, Madrid, Spain.

Rheumatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.

出版信息

Ann Rheum Dis. 2020 Jul;79(7):988-990. doi: 10.1136/annrheumdis-2020-217948. Epub 2020 Jun 5.

DOI:10.1136/annrheumdis-2020-217948
PMID:32503857
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7307213/
Abstract
摘要